Some old news:
Mundipharma has now launched Invokana (canagliflozin) and Vokanamet (canagliflozin, metformin), two treatment options for the management of type 2 diabetes, in Norway.Mundipharma now exclusively distributes these treatments across the whole of Scandinavia, and a total of 18 markets in Europe as part of the exclusive distribution agreement with Janssen, a unit of Johnson & Johnson.
Approximately 58 million people in Europe currently live with the condition, which is on the rise and predicted to affect 67 million people by 2045. If left untreated, patients are at greater risk of developing serious complications, such as cardiovascular disease and kidney failure.
https://www.thepharmaletter.com/in-brief/brief-mundipharma-launches-invokana-and-vokanamet-in-norway
Some old news:Mundipharma has now launched Invokana...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
-0.015(4.41%) |
Mkt cap ! $53.14M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.5¢ | $75.67K | 227.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9093 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 2200 | 1 |
View Market Depth
| Last trade - 15.02pm 24/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |